Retatrutide + Semaglutide
Phase 3Active 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus, Type 2
Conditions
Diabetes Mellitus, Type 2
Trial Timeline
Feb 21, 2024 โ Jan 1, 2027
NCT ID
NCT06260722About Retatrutide + Semaglutide
Retatrutide + Semaglutide is a phase 3 stage product being developed by Eli Lilly for Diabetes Mellitus, Type 2. The current trial status is active. This product is registered under clinical trial identifier NCT06260722. Target conditions include Diabetes Mellitus, Type 2.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06260722 | Phase 3 | Active |
Competing Products
20 competing products in Diabetes Mellitus, Type 2